Brought to you by 
Sankyo and X-Ceptor research liver receptor
18 Feb 2002
Executive Summary
X-Ceptor Therapeutics (developing small-molecule drugs that act on orphan nuclear receptors) signed a three-year R&D agreement with Sankyo to develop and optimize synthetic ligands that act on the liver X receptor, which regulates cholesterol.
Deal Industry
- Biotechnology
- Pharmaceuticals
Deal Status
- Final
Deal Type
-
Alliance
- R&D and Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Sankyo and X-Ceptor research liver receptor
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice